LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

Home・Akciju saraksts・Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

70.03 -0.07

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

69.2

Max

70.37

Galvenie mērījumi
By Trading Economics
Ienākumi	155M -24M
Pārdošana	229M 256M
Peļņas marža	-9.26
Darbinieki	711
EBITDA	-546M -148M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+1.55% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	3.4B 9.5B
Iepriekšējā atvēršanas cena	70.1
Iepriekšējā slēgšanas cena	70.03

Ziņu noskaņojums

By Acuity

21%

79%

37 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

11.5 / 12.23 Atbalsts un pretestība

Arrowhead Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 24. dec. 21:41 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

2025. g. 26. dec. 20:22 UTC

Tirgus saruna

Oil Loses Ground On Russia-Ukraine Peace Efforts -- Market Talk

2025. g. 26. dec. 20:13 UTC

Tirgus saruna

U.S. Natural Gas Gains on Colder Weather Outlook -- Market Talk

2025. g. 26. dec. 19:24 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia's Groq Deal Is an Instagram Moment -- With 1 Big Risk -- Barrons.com

2025. g. 26. dec. 17:45 UTC

Tirgus saruna

U.S. Diesel Down on Lower Crude Prices, Freight-Sector Lull -- Market Talk

2025. g. 26. dec. 15:52 UTC

Tirgus saruna

Oil Futures Turn Lower After Steady Start -- Market Talk

2025. g. 26. dec. 14:58 UTC

Tirgus saruna

Silver, Gold Reach New Highs Amid Geopolitical Tension -- Market Talk

2025. g. 26. dec. 14:41 UTC

Tirgus saruna

U.S. Natural Gas Futures Look to End Week Higher -- Market Talk

2025. g. 26. dec. 14:28 UTC

Tirgus saruna

Dollar Indexes Flat as Yen Rally Wanes -- Market Talk

2025. g. 26. dec. 13:47 UTC

Tirgus saruna

Oil Futures Steady in Thin Holiday Trade -- Market Talk

2025. g. 26. dec. 07:22 UTC

Tirgus saruna

Comex Gold Futures' Strong Bullish Momentum in Play, Chart Shows -- Market Talk

2025. g. 26. dec. 05:03 UTC

Tirgus saruna

Malaysian Ringgit Likely to Face Pressure From Dollar Strength in 1Q -- Market Talk

2025. g. 26. dec. 03:38 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 26. dec. 03:38 UTC

Tirgus saruna

Korean Won Strengthens, Supported by Verbal Interventions -- Market Talk

2025. g. 26. dec. 02:44 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 26. dec. 02:44 UTC

Tirgus saruna

Singapore Dollar Weakens Slightly on Likely Position Adjustments -- Market Talk

2025. g. 26. dec. 01:39 UTC

Tirgus saruna

China's Central Bank Signals Possibility of Easing Policy in Coming Months -- Market Talk

2025. g. 26. dec. 01:14 UTC

Tirgus saruna

Oil Edges Higher Amid Geopolitical Tensions -- Market Talk

2025. g. 26. dec. 00:34 UTC

Tirgus saruna

Yen Mostly Weakens Amid Risk-on Sentiment -- Market Talk

2025. g. 26. dec. 00:15 UTC

Tirgus saruna

Nikkei Gains 0.6%, Led by Tech, Videogame Stocks -- Market Talk

2025. g. 25. dec. 23:42 UTC

Tirgus saruna

Nikkei May Trade in Range; Yen in Focus -- Market Talk

2025. g. 25. dec. 23:40 UTC

Tirgus saruna

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

2025. g. 25. dec. 00:20 UTC

Iegādes, apvienošanās, pārņemšana

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

2025. g. 24. dec. 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

2025. g. 24. dec. 21:26 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

2025. g. 24. dec. 19:35 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 24. dec. 19:35 UTC

Tirgus saruna

Treasury Yields Decline Ahead of Christmas -- Market Talk

2025. g. 24. dec. 19:09 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Global Equities Roundup: Market Talk

2025. g. 24. dec. 19:09 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

2025. g. 24. dec. 19:06 UTC

Tirgus saruna

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

Salīdzinājums

Cenas izmaiņa

Arrowhead Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

1.55% augšup

Prognoze 12 mēnešiem

Vidējais 71.25 USD 1.55%

Augstākais 100 USD

Zemākais 48 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Arrowhead Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

9 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 9 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Arrowhead Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

11.5 / 12.23Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

There is one bearish event.

Noskaņojums

By Acuity

37 / 374 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.